HRP20201187T1 - Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 - Google Patents
Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 Download PDFInfo
- Publication number
- HRP20201187T1 HRP20201187T1 HRP20201187TT HRP20201187T HRP20201187T1 HR P20201187 T1 HRP20201187 T1 HR P20201187T1 HR P20201187T T HRP20201187T T HR P20201187TT HR P20201187 T HRP20201187 T HR P20201187T HR P20201187 T1 HRP20201187 T1 HR P20201187T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- intended
- derivative useful
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (10)
1. Spoj, naznačen time što je spoj formule:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je:
[image]
.
3. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u terapiji.
4. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju kronične bolesti bubrega.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju dijabetične bolesti bubrega.
6. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s patentnim zahtjevom 1, uz jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
7. Postupak priprave farmaceutskog pripravka, naznačen time što se sastoji u miješanju spoja u skladu s patentnim zahtjevom 1, ili njegove farmaceutski prihvatljive soli, s jednim ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
8. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u liječenju kronične bolesti bubrega.
9. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u liječenju dijabetične bolesti bubrega.
10. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 2, uz jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379372P | 2016-08-25 | 2016-08-25 | |
| PCT/US2017/047479 WO2018039051A1 (en) | 2016-08-25 | 2017-08-18 | Triazolopyrazinone derivative useful as a human pde1 inhibitor |
| EP17761381.7A EP3504208B1 (en) | 2016-08-25 | 2017-08-18 | Triazolopyrazinone derivative useful as a human pde1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201187T1 true HRP20201187T1 (hr) | 2020-11-13 |
Family
ID=59762063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201187TT HRP20201187T1 (hr) | 2016-08-25 | 2020-07-29 | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10138244B2 (hr) |
| EP (1) | EP3504208B1 (hr) |
| JP (1) | JP6633246B2 (hr) |
| KR (1) | KR20190028544A (hr) |
| CN (1) | CN109641902B (hr) |
| AR (1) | AR109328A1 (hr) |
| AU (1) | AU2017317111A1 (hr) |
| BR (1) | BR112019000988A2 (hr) |
| CA (1) | CA3034828A1 (hr) |
| CL (1) | CL2019000487A1 (hr) |
| CO (1) | CO2019001644A2 (hr) |
| CR (1) | CR20190078A (hr) |
| CY (1) | CY1123406T1 (hr) |
| DK (1) | DK3504208T3 (hr) |
| DO (1) | DOP2019000021A (hr) |
| EA (1) | EA201990313A1 (hr) |
| EC (1) | ECSP19013196A (hr) |
| ES (1) | ES2800433T3 (hr) |
| HR (1) | HRP20201187T1 (hr) |
| HU (1) | HUE050419T2 (hr) |
| JO (1) | JOP20170164A1 (hr) |
| LT (1) | LT3504208T (hr) |
| MA (1) | MA46039B1 (hr) |
| MD (1) | MD3504208T2 (hr) |
| ME (1) | ME03791B (hr) |
| MX (1) | MX2019002065A (hr) |
| PE (1) | PE20190452A1 (hr) |
| PH (1) | PH12019500370A1 (hr) |
| PL (1) | PL3504208T3 (hr) |
| PT (1) | PT3504208T (hr) |
| RS (1) | RS60442B1 (hr) |
| SG (1) | SG11201901311WA (hr) |
| SI (1) | SI3504208T1 (hr) |
| SV (1) | SV2019005838A (hr) |
| TN (1) | TN2019000038A1 (hr) |
| TW (1) | TWI651323B (hr) |
| WO (1) | WO2018039051A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| AR112346A1 (es) | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
| US11453673B2 (en) | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| EP2103613B1 (en) * | 2006-12-13 | 2016-02-17 | ASKA Pharmaceutical Co., Ltd. | Quinoxaline derivative |
| WO2008103357A1 (en) | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
| CN103097393B (zh) | 2010-09-07 | 2015-09-16 | 安斯泰来制药株式会社 | 喹喔啉化合物 |
| BR112014031730B1 (pt) * | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
| US9938284B2 (en) * | 2014-08-07 | 2018-04-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20160083400A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
-
2016
- 2016-08-25 JO JOP/2017/0164A patent/JOP20170164A1/ar unknown
-
2017
- 2017-08-11 AR ARP170102252A patent/AR109328A1/es unknown
- 2017-08-11 TW TW106127199A patent/TWI651323B/zh not_active IP Right Cessation
- 2017-08-18 CN CN201780050004.2A patent/CN109641902B/zh active Active
- 2017-08-18 WO PCT/US2017/047479 patent/WO2018039051A1/en unknown
- 2017-08-18 BR BR112019000988-4A patent/BR112019000988A2/pt not_active IP Right Cessation
- 2017-08-18 PE PE2019000371A patent/PE20190452A1/es unknown
- 2017-08-18 CR CR20190078A patent/CR20190078A/es unknown
- 2017-08-18 EP EP17761381.7A patent/EP3504208B1/en active Active
- 2017-08-18 MD MDE20190732T patent/MD3504208T2/ro unknown
- 2017-08-18 CA CA3034828A patent/CA3034828A1/en not_active Abandoned
- 2017-08-18 RS RS20200738A patent/RS60442B1/sr unknown
- 2017-08-18 DK DK17761381.7T patent/DK3504208T3/da active
- 2017-08-18 US US15/680,250 patent/US10138244B2/en active Active
- 2017-08-18 PL PL17761381T patent/PL3504208T3/pl unknown
- 2017-08-18 JP JP2019510969A patent/JP6633246B2/ja active Active
- 2017-08-18 PT PT177613817T patent/PT3504208T/pt unknown
- 2017-08-18 MX MX2019002065A patent/MX2019002065A/es unknown
- 2017-08-18 EA EA201990313A patent/EA201990313A1/ru unknown
- 2017-08-18 TN TNP/2019/000038A patent/TN2019000038A1/en unknown
- 2017-08-18 SG SG11201901311WA patent/SG11201901311WA/en unknown
- 2017-08-18 MA MA46039A patent/MA46039B1/fr unknown
- 2017-08-18 ME MEP-2020-144A patent/ME03791B/me unknown
- 2017-08-18 AU AU2017317111A patent/AU2017317111A1/en not_active Abandoned
- 2017-08-18 LT LTEP17761381.7T patent/LT3504208T/lt unknown
- 2017-08-18 ES ES17761381T patent/ES2800433T3/es active Active
- 2017-08-18 SI SI201730305T patent/SI3504208T1/sl unknown
- 2017-08-18 KR KR1020197005013A patent/KR20190028544A/ko not_active Application Discontinuation
- 2017-08-18 HU HUE17761381A patent/HUE050419T2/hu unknown
-
2019
- 2019-01-30 DO DO2019000021A patent/DOP2019000021A/es unknown
- 2019-02-19 SV SV2019005838A patent/SV2019005838A/es unknown
- 2019-02-21 PH PH12019500370A patent/PH12019500370A1/en unknown
- 2019-02-22 CO CONC2019/0001644A patent/CO2019001644A2/es unknown
- 2019-02-22 EC ECSENADI201913196A patent/ECSP19013196A/es unknown
- 2019-02-22 CL CL2019000487A patent/CL2019000487A1/es unknown
-
2020
- 2020-07-29 HR HRP20201187TT patent/HRP20201187T1/hr unknown
- 2020-08-14 CY CY20201100760T patent/CY1123406T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171512T1 (hr) | Derivati betulina | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| RU2017105353A (ru) | Соединения | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| WO2016205475A3 (en) | Tgr5 modulators and methods of use thereof | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201791727A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии | |
| EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
| JP2016510326A5 (hr) | ||
| CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза |